|
|
|
|
| LEADER |
00000cam a22000003 4500 |
| 001 |
EBOOKCENTRAL_ocn948966340 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
160329nuuuuuuuuxx o 000 0 eng d |
| 040 |
|
|
|a YDXCP
|b eng
|e pn
|c YDXCP
|d EBLCP
|d OCLCQ
|d SFB
|d OCLCF
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 951065178
|
| 020 |
|
|
|a 1681080761
|q (electronic bk.)
|
| 020 |
|
|
|a 9781681080765
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)948966340
|z (OCoLC)951065178
|
| 050 |
|
4 |
|a RA645.C3
|b T67 2015
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Editor: Atta-Ur-Rahman, Khurshid Zaman.
|
| 245 |
0 |
0 |
|a Topics in anti-cancer research volume 4.
|
| 260 |
|
|
|a [Place of publication not identified] :
|b Bentham Science Publisher
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Topics in Anti-Cancer Research ;
|v v. 1
|
| 505 |
0 |
|
|a FOREWORD ; List of Contributors ; Targeted Cancer Therapy: The Roles Played by Antibody-Drug and Antibody-Toxin Conjugates ; 1. INTRODUCTION; 2. IMMUNOTOXINS; 2.1. Pseudomonas Exotoxin-Based Immunotoxins; 2.2. Pseudomonas Exotoxin-Based ITs in Treating Solid Tumors; 2.3. Diphtheria Toxin-Based Immunotoxins; 2.4. Ribosome Inactivating Proteins-Based Immunotoxins; 2.4.1. Ricin; 2.4.2. Recombinant constructs of RIP I toxins; 2.5. Ribonucleases-Based IT; 2.6. Proapoptotic Proteins Used As Targeted Immunotoxins/Chimeric Proteins; 2.7. Current & Future Developments of ITs.
|
| 505 |
8 |
|
|a 3. ANTIBODY-DRUG CONJUGATES 3.1. DNA Interacting Agents-Calicheamicins; 3.2. DNA Interacting Agents-Duocarmycins; 3.3. DNA Interacting Agents-Pyrrolo[1,4]Benzodiazepines; 3.4. Tubulin Interacting Agents-Auristatins; 3.5. Tubulin Interacting Agents-Maytansinoids; 3.6. Other Anticancer Drugs Conjugated to mAbs; 4. CURRENT AND FUTURE DEVELOPMENTS OF ADC ; DISCLOSURE; CONFLICTS OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Targeting Cell Surface Nucleolin in Cancer ; INTRODUCTION; CELL SURFACE LOCALIZATION OF NCL; LIGANDS OF CELL SURFACE NCL.
|
| 505 |
8 |
|
|a CELL SURFACE NCL-DEPENDENT LIGAND SPECIFIC INTERNALIZATIONCELL SURFACE NCL AND SIGNALING COMPLEXES; TARGETING CELL SURFACE NCL; CELL SURFACE NCL AS BIOMARKER FOR CANCER; PATENTS RELATED TO NCL; CURRENT & FUTURE DEVELOPMENTS; DISCLOSURE; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Anticancer Agents Targeting Tubulin ; 1. INTRODUCTION; 2. MICROTUBULE DESTABLIZERS; 2.1. Colchicine; 2.2. Combretastatin A-4 (CA-A4); 2.3. Chalcones; 2.4. Phenstatins; 2.5. Podophyllotoxin; 2.6. Vinca Alkaloids; 2.7. Other Tubulin Polymerization Inhibitors; 3. MICROTUBULE STABLIZERS; 3.1. Taxol®
|
| 505 |
8 |
|
|6 880-01
|a 4.12. Cytopia Pty Ltd Patents4.13. Galemmo et al. Patents; 4.14. Pettit et al. Patents; 4.15. Patent by Aneja et al.; 4.16. Wyeth Holding Corporation Patents; 4.17. Champions Biotechnologypatents; 4.18. Bionomics Ltd. Patents; 4.19. Janssen Pharmaceutica Patents; 4.20. Exonhit Patents; 4.21. Centre National De La Recherche Scientifique Patents; 4.22. Development Centre of Biotechnology Patents; 4.23. Y M Biosciences Pty Ltd. Patents ; 4.24. Patents by Gangjee et al.; 4.25. Thorson et al. Patents; 4.26. Bionomics Ltd. Patents ; 4.27. Chen et al. (2014); 4.28. Wang et al. (2014).
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Cancer
|x Research.
|
| 650 |
|
0 |
|a Cancer
|x Prevention.
|
| 650 |
|
6 |
|a Cancer
|x Recherche.
|
| 650 |
|
6 |
|a Cancer
|x Prévention.
|
| 650 |
|
7 |
|a Cancer
|x Prevention
|2 fast
|
| 650 |
|
7 |
|a Cancer
|x Research
|2 fast
|
| 758 |
|
|
|i has work:
|a Topics in anti-cancer research volume 4 (Text)
|1 https://id.oclc.org/worldcat/entity/E39PD36TwdMr3QxWqQ4RRJJp4C
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur Rahman,
|t Topics in Anti-Cancer Research.
|d Sharjah : Bentham Science Publishers, ©2015
|z 9781681080772
|
| 830 |
|
0 |
|a Topics in Anti-Cancer Research.
|
| 856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=4412614
|z Texto completo
|
| 880 |
8 |
|
|6 505-01/(S
|a 3.2. Other Tubulin Depolymerization InhibitorsDrugs Bind to Microtubule-Associated Proteins (MAPs); Peripheral Neuropathy Induced by Anti Mitotic Agents [177]; Role of β-Tubulin Isotypes in Drug Binding [178]; 4. RECENT PATENTS; 4.1. Research Corporation Technologies Patents; 4.2. Brandeis University Patents; 4.3. Tuse et al. Patents; 4.4. Pinney et al. Patents; 4.5. Aventis Pharma Patents (2001); 4.6. Davis et al. Patents; 4.7. Aventis Pharma Patents (2003); 4.8. Chang et al. Patents; 4.9. Hadfield et al. Patents; 4.10. Rigel Pharmaceuticals Patents; 4.11. NIH Patents.
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4412614
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 12691319
|
| 994 |
|
|
|a 92
|b IZTAP
|
